From 303 atoms to 12,635: the 2026 protein simulation curve, and who it is built for | Burgeon Studio Insights
Market Intelligence16 July 2026

From 303 atoms to 12,635: the 2026 protein simulation curve, and who it is built for.

In March, Cleveland Clinic and IBM described a 303 atom miniprotein simulation on quantum hardware. In May, the same partnership, joined by RIKEN, reported complexes about forty times larger. We look at what actually improved, what still has not, and at the access question the field is not yet answering.

By Burgeon Studio Research TeamEstimated read: 7 minutes

Forty times the scale between two announcements

On 23 March 2026, IBM described how a Cleveland Clinic and IBM team simulated the electronic structure of Trp-cage, a 303 atom miniprotein, using an IBM Quantum Heron r2 processor working with classical high performance computing1. IBM presented it as the first time a protein’s electronic structure had been simulated this way.

On 5 May, IBM announced a result roughly forty times larger, this time with RIKEN joining the collaboration2. The team simulated two protein ligand complexes in explicit water: T4 Lysozyme with 11,608 atoms and trypsin with 12,635 atoms. They sampled electronic configurations on two 156 qubit IBM processors, using up to 94 qubits, while the Fugaku and Miyabi-G supercomputers did the classical work3,4. The preprint reports a more than 40 fold increase in system size, and up to a 210 fold improvement in accuracy on a key step of the workflow, not on the overall simulation3,4.

The pace matters more than either individual result. Quantum simulation in life sciences has spent a decade being described as five years away, and here the scale of what was demonstrated grew about forty times between two announcements.

The two results side by side. Switch to a log scale to see both clearly.

The scale curve bent sharply this year. Whether it bends toward everyone, or just the institutions that already had a head start, is still an open question.

What actually improved, and what has not

The technique behind both results is what IBM calls quantum centric supercomputing: classical computers fragment a protein into computationally manageable clusters, and quantum hardware handles the most complex of those clusters, with the two systems working in tandem rather than the quantum processor attempting the whole problem alone1.

It is worth stating plainly, in the same spirit we hold ourselves to on this site: neither announcement claims that the method beats the best classical approaches. IBM’s March post describes the workflow as competitive with classical approaches1, and the May preprint reports fragment energies that match CCSD accuracy, a well established classical benchmark3. Independent commentary is blunter: it does not yet outperform the best purely classical methods for protein chemistry4. Showing that a hybrid workflow can be built and scaled quickly is a different claim from showing that quantum hardware has overtaken classical computation, and the industry has a poor record of keeping the two apart.

Who has access, and who does not

A quieter theme has been building alongside these headlines. A Nature Biotechnology editorial published on 6 July argues that early quantum access will be uneven: a few large pharmaceutical companies, national laboratories and well funded universities are likely to gain first mover advantages. It warns that neglected tropical diseases, and antimicrobial resistance in low income settings, will not be early beneficiaries of quantum accelerated biology5.

That is not a criticism of the researchers doing the work. The Cleveland Clinic, RIKEN and IBM results above are genuine science, openly published. It is an observation about infrastructure: who owns the hardware shapes which biology gets simulated first.

What this means for teams building here

  • The demonstrated scale is moving fast. Plan roadmaps with that in mind, and check them again often.
  • “Quantum advantage” and “quantum utility” are not the same claim. Read every announcement for which one is actually being made.
  • Access to hardware is not the same as access to results. The software layer is where smaller teams can still compete.

This is the gap our own “Accessible by design” principle is built around. Cloud delivered software does not require a research hospital’s hardware budget, but it does require someone to build it. It is also why we are AI native first: AI and classical methods solve most problems today, and we add quantum only where a problem is beyond what AI can handle.

Sources
  1. IBM Quantum blog, “Cleveland Clinic and IBM debut new quantum simulation workflow” (23 March 2026).
  2. IBM Newsroom, “Cleveland Clinic, RIKEN, and IBM Model a 12,635 Atom Protein” (5 May 2026).
  3. Merz, Motta, Yunoki and colleagues, “Crossing the 12,000 atom barrier with heterogeneous quantum classical supercomputing: quantum chemistry of protein ligand complexes,” arXiv 2605.01138 (submitted 1 May 2026).
  4. PostQuantum, “Quantum Computing Simulates 12,635 Atom Protein,” independent analysis.
  5. Nature Biotechnology editorial, “Quantum computing in transition,” volume 44, pages 1065 to 1066 (6 July 2026).

Atom counts, qubit counts and the 40 fold and 210 fold figures are as reported by IBM and in the preprint. Statements about our own approach are Burgeon Studio’s view.